Direct effects of the prostaglandins E2 and f2alpha on progesterone release by the corpus luteum of the marmoset monkey (Callithrix jacchus) studied by in vitro microdialysis.
The effects of the prostaglandins (PG) E2 and F2alpha on progesterone secretion in luteal tissue (32 corpora lutea) explanted from the mid-luteal ovary of the marmoset monkey (n=13) were investigated using an in vitro microdialysis system. Consecutive applications of 1, 10 and 100 microg/ml PGE2 resulted in a significant increase in secretion of progesterone at the maximum dose of 100 microg/ml, which was shown to be the stimulatory dose in both long-period and 20-min pulse (time to collect one fraction) applications. The response varied individually between 1.4- and 3. 4-fold above the baseline concentrations. Application of 500 microg/ml PGF2alpha led to similar hormone responses. In contrast, lower doses of PGF2alpha (0.5, 5 and 50 microg/ml) resulted in significantly increased levels of secretion of progesterone, to approximately 1.4-fold baseline values, only after the application was terminated (echo effect). Responses were less variable when a short pulse of 20 min duration was applied, instead of long applications of 1-2 h. On the basis of the passage rates measured for tritiated PGF2alpha, transfer through the dialysis membrane was assumed to be in the range of 1% for both PGs. Ultrastructurally, luteal cells lying in a sheath of five to seven cell layers around the dialysis tubing appeared intact and were interconnected by gap junctions. Vesiculation of the smooth endoplasmic reticulum was more prominent after PG treatment, indicating a stimulation of cellular synthesis/secretory activities that was in accordance with the stimulatory action of both PGs on progesterone release under these in vitro conditions.
Fehrenbach
A
A
Centre of Anatomy, Electron Microscopy, University of Göttingen, Kreuzbergring 36, D-37075 Göttingen, Germany.
Hodges
J K
JK
Einspanier
A
A
D000818:Animals; D002144:Callithrix; D003338:Corpus Luteum / Q000378:metabolism* / Q000648:ultrastructure; D015237:Dinoprost / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D008183:Luteal Phase; D017551:Microdialysis; D011374:Progesterone / Q000378:metabolism*; D011453:Prostaglandins / Q000494:pharmacology*
D011453:Prostaglandins; D011374:Progesterone; D015237:Dinoprost; D015232:Dinoprostone